Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
54.850USD
-2.590-4.51%
Market hours 11/03, 09:40（ET）
10.62BMarket Cap
39.32P/E TTM
BioMarin Pharmaceutical Inc (BMRN) Stock Price Target & Forecast
Analyst Rating
Based on 29 analysts giving stock ratings to BioMarin Pharmaceutical Inc in the past month.
Buy
8 Strong Buy
14 Buy
7 Hold
0 Sell
0 Strong Sell
Target Price
91.543USD+63.47%
BMRN Analyst Recommendation Trends
In the current month, BMRN has received 14 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the last month is 91.543.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
8
8
8
8
9
9
8
8
14
14
14
13
13
13
13
12
7
7
7
6
6
6
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
29
29
27
28
28
26
25
BMRN Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
15
9
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, BMRN EPS is projected to reach 1.163 in FY2026Q4, following reported EPS of -0.634 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.75
0.69
0.12
1.16
1.15
Actual
0.55
0.23
-0.63
--
--
Surprise
-26.97%
-66.35%
-634.13%
--
--
FAQs
What is BioMarin Pharmaceutical Inc's expected revenue for the next quarter?
BioMarin Pharmaceutical Inc's expected revenue is 1.14B.
What is BioMarin Pharmaceutical Inc's price target?
Analysts forecast that BioMarin Pharmaceutical Inc's price target is USD 91.54, with the highest forecast at USD 122.00 and the lowest forecast at USD 60.00.
How have BioMarin Pharmaceutical IncBMRN's recent earnings per share performed?
The market expectation was USD 0.23, while BioMarin Pharmaceutical IncBMRN's earnings per share (EPS) for the previous quarter was USD 0.55. EPS for the next quarter is expected at USD 0.12.
What is the analyst rating for BioMarin Pharmaceutical Inc?
Based on the ratings of BioMarin Pharmaceutical Inc's stock from 29 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.